Navigation Links
Bi-Coastal Pharmaceutical Corp. Acquires U.S. Marketing Rights to Aquoral(TM) Artificial Saliva Product

Exclusive prescription spray product to treat Xerostomia will compete in $1 Billion US Market

RED BANK, N.J., Dec. 11 /PRNewswire/ -- Bi-Coastal Pharmaceutical Corp. announced today that it has acquired the US marketing rights to Aquoral(TM) artificial saliva. Aquoral(TM) is a lipid based artificial saliva spray product that is currently the only Prescription spray product marketed in the United States to treat Xerostomia. The total US market for products treating Xerostomia was estimated at $1 Billion in 2007. The product is sold in a 40ml (1.4 fl. oz.) spray bottle that if used as directed is a 2 month supply. Aquoral(TM) has already received overwhelming acceptance by physicians as well as patients suffering with Xerostomia. The sales and marketing of Aquoral(TM) will begin by Bi-Coastal to the Pharmaceutical trade channels immediately.

Bi-Coastal Pharmaceutical Corp. is a leading Sales, Marketing and Consulting company founded in 1982 and based in Red Bank, New Jersey. Since 2001, Bi-Coastal has secured product sales in excess of $650 Million. Bi-Coastal is currently finalizing its multi-faceted sales and marketing plans for Aquoral(TM) that will include an aggressive trade and physician advertising campaign, telemarketing, direct mail and other programs to physicians as well as a detail sales force initially targeting the Dental, Oncology, Rheumatology and Managed Care markets.

Ralph Massa, Jr., Bi-Coastal Pharmaceutical Corp.'s President and Chief Operating Officer stated the following, "I am pleased to announce the acquisition of Aquoral(TM) and confident that we will achieve significant sales levels well within the first year of marketing the product. Aquoral(TM) will soon be a trusted and proven household name to treat Xerostomia as it is an extremely effective and easy to use product with no known adverse effects. We look forward to the official re-launch of Aquoral(TM) to the trade at the upcoming ECRM conference in Destin, Florida next month as well as discussing many other products that will be a part of Bi-Coastal's exciting product portfolio in 2009."

    For more information please contact:

    Ralph Massa, Jr.
    President and Chief Operating Officer
    Bi-Coastal Pharmaceutical Corp.
    130 Maple Avenue
    Red Bank, New Jersey 07701
    Tel-(732) 530-6606 Ext 132
    Fax-(732) 530-1521

SOURCE Bi-Coastal Pharmaceutical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AlphaDetail, Inc. Continues Bi-coastal Expansion
2. Employer Vantage From HealthLeaders-InterStudy Provides a Snapshot of Both Self- and Fully-Insured Health Benefits to Help Pharmaceutical and Diagnostic Manufacturers Identify Business Opportunities
3. Napo Pharmaceuticals Announces License of Crofelemer to Salix Pharmaceuticals
4. Synovics Pharmaceuticals Announces Additional Investment by Svizera and Reduction of Debt
5. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
6. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
7. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
8. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
9. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
10. Pharmaceutical Water Markets, the Economic Crunch Creates New Opportunities in Southern and Eastern Europe
11. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference
Post Your Comments:
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... conversation at the recent 2015 American Dental Association meeting in Washington D.C. revolved around ... help protect a patient’s overall health. The talk stressed the link between periodontal disease ...
(Date:11/27/2015)... ... 27, 2015 , ... An inventor, from Hopkinsville, Ky., thought ... at home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. ... doing so, it could help to prevent potential overdose situations. As a result, ...
(Date:11/27/2015)... ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed ... 1-1 ). More than 3.7 billion people under the age of 50 – or ... to WHO's first global estimates of HSV-1 infection . , "The data shocks us ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping ... platform for mental health and wellness consultation, has collaborated with a leading web-based ... the knowledge gap experienced by parents and bring advice from parenting experts within ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 3D bioprinting market ... according to a new report by Grand View Research Inc. ... (CKD) which demands kidney transplantation is expected to boost the ... substitute for organ transplantation. --> 3D bioprinting market ... according to a new report by Grand View Research Inc. ...
(Date:11/26/2015)... 26, 2015 ... ser potential att använda SyMRI för att ... för patienter med multipel skleros (MS) eller ... SyntheticMR AB för att kunna använda SyMRI ... Med SyMRI kan man generera flera konstrastbilder ...
(Date:11/26/2015)... 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in the ... Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new 247-page ... therapeutic drug monitoring market, including emerging tests, technologies, ...
Breaking Medicine Technology: